Agilent Technologies (NYSE:A) Price Target Cut to $165.00 by Analysts at HSBC

Agilent Technologies (NYSE:A) had its target price dropped by research analysts at HSBC from $180.00 to $165.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. HSBC’s target price would indicate a potential upside of 19.08% from the stock’s current price.

A number of other research analysts have also issued reports on A. Wells Fargo & Company reduced their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. UBS Group dropped their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank Of Canada started coverage on Agilent Technologies in a research note on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 price objective on the stock. Finally, Morgan Stanley dropped their target price on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $161.71.

Agilent Technologies Stock Performance

Shares of A traded up $3.51 during midday trading on Wednesday, reaching $138.56. 1,163,359 shares of the stock were exchanged, compared to its average volume of 2,262,655. The business’s 50-day moving average price is $116.42 and its 200 day moving average price is $128.54. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62. Agilent Technologies has a twelve month low of $108.35 and a twelve month high of $160.27. The company has a market capitalization of $39.16 billion, a price-to-earnings ratio of 27.82, a PEG ratio of 2.77 and a beta of 1.26.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.08. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The firm had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same period last year, the firm posted $1.31 EPS. Agilent Technologies’s quarterly revenue was up 10.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, sell-side analysts expect that Agilent Technologies will post 5.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of A. Brighton Jones LLC grew its stake in shares of Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after purchasing an additional 270 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Agilent Technologies by 15.9% in the 1st quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock worth $602,000 after purchasing an additional 769 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Agilent Technologies by 54.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock worth $70,000 after purchasing an additional 212 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Agilent Technologies by 16.5% in the 1st quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock worth $625,000 after purchasing an additional 758 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Agilent Technologies in the 2nd quarter worth approximately $273,000.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.